Calibr-Skaggs announces initial dosing of a first-in-class regenerative lung medicine in a phase 1 trial for idiopathic pulmonary fibrosis CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
October 30, 2024
LA JOLLA, CA The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that the first dose of a pioneering regenerative lung therapy, CMR316, has been given in a phase 1 trial assessing safety and tolerability in healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF). This once-weekly, inhaled drug has potential to revolutionize treatment of lung diseases by stimulating stem cells to regenerate damaged lung tissue.
There are currently no regenerative treatments for any lung disease, including IPF, which is a deadly condition characterized by extensive tissue damage and permanent lung scarring, says Chan Beals, MD, chief medical officer of Calibr-Skaggs. Based on our encouraging preclinical data, CMR316 has the potential to halt or even reverse IPF, in addition to other severe lung conditions such as chronic obstructive pulmonary disease. This clinical milestone achieved through the collaborative bench to bedside' model of Scripps Research and Calibr-Skaggs scientists brings us closer to delivering a first-in-class medicine that could transform the lives of many people affected by debilitating lung diseases.
IPF is a severe, chronic, and progressive disease with no known cause and no cure. It affects roughly 100,000 people in the United States, drastically reducing their quality of life. With ever-increasing fibrosis in the lung over time, IPF progresses from mild shortness of breath and dry cough during activity to an inability to breathe even at rest. Difficulty breathing can lead to pulmonary hypertension and respiratory failure, preventing the brain and other organs from receiving adequate oxygen. There is no cure for IPF, aside from a lung transplant which is rarely an option, and tragically, patient survival after diagnosis is a mere 2 5 years. Available treatments, such as anti-fibrotics, can only slow disease progression and manage symptoms, highlighting the critical need for innovative new therapies. With an understanding that the lung's natural yet limited capacity to regenerate and repair is impaired in IPF, a new therapeutic strategy has emerged.
CMR316 is a first-in-class drug designed to precisely stimulate lung stem cells to regenerate lung tissue. Specifically, CMR316 targets type 2 alveolar epithelial cells (AEC2s) the stem cells in the lower airway of the lungs that are reduced in patients with IPF. Stimulating AEC2 stem cells causes them to differentiate into type 1 AEC (AEC1) cells that are crucial for gas exchange and maintaining lung stability and function. Thus, stimulating AEC2 stem cells with CMR316 has potential to repair damage caused by many lung conditions, including IPF. Furthermore, CMR316's regenerative mechanism is distinct yet complementary to that of approved anti-fibrotics, which could allow them to be combined for even greater effect.
CMR316 was discovered and developed through a partnership between Scripps Research and Calibr-Skaggs scientists, led by President and CEO Peter Schultz, PhD, and Associate Professor of Chemistry Michael Bollong, PhD, who is the Early Endowed Roon Chair for Cardiovascular Research. In April 2024, they published a study in the Proceedings of the National Academy of Sciences, which provided proof of concept for CMR316's ability to stimulate AEC2s to regenerate lung tissue in IPF and several other lung disease models.
From this foundational bench' research, the Calibr-Skaggs drug development team, led by Vice President of Pharmacology Sean Joseph, PhD, performed critical preclinical safety studies and received regulatory approval to reach the bedside' for testing CMR316 in humans.
Through careful testing of CMR316 over the last few years a huge team effort we are cautiously optimistic that the benefits and exceptional safety profile we observed preclinically will translate to patients with lung diseases, including those with IPF, says Joseph.
CMR316 is being tested at Fraunhofer ITEM in Hanover, Germany in an extensive phase 1 study in healthy volunteers (Parts 1 and 2) and patients with IPF (Part 3). The study title is A Phase 1/1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Nebulized CMR316 in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis (EU trial number: 2023-510456-23-00). The main objective of the trial is to assess the safety and tolerability of single (Part 1) and multiple inhaled doses of CMR316 in healthy volunteers (Part 2) and patients with IPF (Part 3).
This work was supported by funding from Calibr-Skaggs, with additional support from the Bachrach Family Foundation.
Calibr-Skaggs Schultz, Peter Bollong, Michael
Most recent headlines
25/12/2025
Holiday lights are twinkling, hot cocoa's on the stove and gamers are settling in for a well-earned break.
Whether staying in or heading on a winter getawa...
24/12/2025
What is AI good for? Posted by MTI Film on December 24, 2025
What is AI good for?
What is AI good for?
It's been three years since ChatGPT first cap...
24/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
24/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
24/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
24/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
24/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
24/12/2025
Back to All News
The Boyfriend' Season 2 Unveils Heartwarming Trailer, Key...
24/12/2025
Back to All News
Love, Fights, and Everything in Between: Badly in Love' Returns for Season 2
Entertainment
24 December 2025
GlobalJapan
Link copied t...
24/12/2025
Scripps Research study links sleep variability with sleep apnea and hypertension How consumers' digital activity trackers could enable personalized health s...
23/12/2025
How guilas Cibae as Dominican Winter League Games Are Locally Produced for Glob...
23/12/2025
BitFire's Jim Akimchuk on Supplying Scalability and Customization in the Clo...
23/12/2025
CAMB.AI Enables European Athletics to Offer Multi-Language SupportPlan is to eventually offer translation into all languages spoken in EuropeBy Ken Kerschbaumer...
23/12/2025
Analysis: As sports media values trend negative, scarcity and quality are king By Callum McCarthy, Editor-at-Large
Monday, December 22, 2025 - 14:08
Print ...
23/12/2025
ESPN, Disney, and NBA Return to the Animated Altcast Fray With Second Edition of...
23/12/2025
End the Year on a High Note and Donate to the Sports Broadcasting Fund Today! By Ken Kerschbaumer, Editorial Director
Tuesday, December 23, 2025 - 12:25 pm
...
23/12/2025
The year is winding down, the weather outside is frightful, and it's the perfect time to escape into a story that warms the heart. For listeners looking for...
23/12/2025
A Zeus motor is hot fire tested at L3Harris' Camden, Arkansas, solid rocket ...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Lightware will exhibit several major product innovations at ISE 2026, including the new USB-C BOOSTER-V1, Google Meet. integration for various Taurus UCX models...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
23/12/2025
Taking the Stage at Carnegie Hall-On a Global Scale Boston Conservatory Orchestra students reflect on their epic concert marking the 80th session of the UN Gene...
23/12/2025
Back to All News
Netflix's The Great Flood and Culinary Class Wars 2 Top Gl...
23/12/2025
Back to All News
Stranger Things By the Numbers: How the Global Phenomenon Shap...
23/12/2025
Experience the power of WO Automation for Radio's newest service, the System Effectiveness Review. Designed to help you achieve more, a System Effectiveness...
23/12/2025
23 Dec 2025
VEON's Beeline Kazakhstan and Rakuten Symphony Collaborate to A...
23/12/2025
Back to All News
How Steamy Can It Get? Single's Inferno' Season 5 Pre...
23/12/2025
Back to All News
33 Million Global Viewers on Netflix Watched Jake Paul vs. Ant...
23/12/2025
New technique lights up where drugs go in the body, cell by cell Scripps Research scientists developed a technique that maps drug binding in individual cells th...
22/12/2025
SVG New Sponsor Spotlight: Presidio's Neerav Shah on the Role of Its Captiva...
22/12/2025
Hitting the bullseye: Sky Sports readies itself for the biggest PDC World Darts ...
22/12/2025
Unique skillset: Bringing new directors to the world of darts at The Worlds with...
22/12/2025
Gravity Media prepares for a flight of fancy with the PDC World Darts Championsh...
22/12/2025
One hundred and eighty: Gravity Media on hitting the production bullseye at the ...
22/12/2025
The Famous Group's Jon Slusser on Fascinating Fans Through Immersive Content...
22/12/2025
ESPN's Meg Aronowitz on Continuing High-Quality Broadcasts of Collegiate Spo...
22/12/2025
ESPN Takes Data-Driven Storytelling to New Heights with MNF Playbook with Next ...
22/12/2025
For a decade, popular German podcast Fest & Flauschig has hosted an annual Chris...
22/12/2025
Paramount Scores Largest Share Increase Among Distributors as Paramount and CBS...
22/12/2025
New multi-year deal integrates Roku's data to fuel Nielsen's measurement suite
Roku gains access to Nielsen's streaming ratings, showing The Roku C...
22/12/2025
Share Share by:
Copy link
Facebook
X
Whatsapp
Pinterest
Flipboard...
22/12/2025
Berklee Wrapped 2025: Our Top News and Stories A look back at a year highlighted by faculty milestones, major film and television projects, Bob Dylan's ho...
22/12/2025
The works of Plato state that when humans have an experience, some level of change occurs in their brain, which is powered by memory - specifically long-term me...
Calibr-Skaggs announces initial dosing of a first-in-class regenerative lung medicine in a phase 1 trial for idiopathic pulmonary fibrosis CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue.
